Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study
NCT02492074 · Central Institute of Mental Health, Mannheim · PHASE1 · withdrawn · last registry update 2025-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No documents were ever submitted to the Ethics Committee or the competent authority because it was not possible to establish the planned PET measurements in Germany. Therefore, the study never started.” | – | Registry record, Central Institute of Mental Health, Mannheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CNR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-13Also stopped (withdrawn): Baylor College of Medicine, Dronabinol Capsules + Placebo (NCT06834997)
- 2026-03-09Results posted on the registry: Harmony Biosciences Management, Inc., ZYN002 (NCT05149898)
- 2026-02-27Phase 3 first posted: University of Oxford, Cannabidiol (CBD) + Placebo (NCT07434973)
- 2026-02-20Phase 3 first posted: Benuvia Therapeutics Inc., Dronabinol Oral Solution (NCT07422311)
- 2026-01-16Results posted on the registry: Mayo Clinic, Cannabidiol + Placebo Administration (NCT05388058)
- 2026-01-08Phase 3 first posted: University of Oxford, CBD 100 mg/mL Oral Solution + Placeb (NCT07326124)
- 2025-12-09Results posted on the registry: Dartmouth-Hitchcock Medical Center, Marijuana + Dronabinol (NCT01964404)
- 2025-11-26Results posted on the registry: Yale University, CBD Day 1 + CBD Day 2 (NCT05076370)
- 2025-11-24Phase 3 first posted: Khon Kaen University, 10% urea lotion plus 1% cannabidiol + Control (NCT07245238)
- 2025-11-17Phase 3 first posted: Mayo Clinic, Dronabinol + Placebo (NCT07231965)
- 2025-10-31Results posted on the registry: Jazz Pharmaceuticals, GWP42003-P (NCT04485104)
- 2025-10-31Also stopped (terminated): Jazz Pharmaceuticals, GWP42003-P (NCT04485104)
- 2025-10-20Results posted on the registry: Cardiol Therapeutics Inc., CardiolRx (NCT05494788)
- 2025-10-15Results posted on the registry: Albert Einstein College of Medicine, Cannabis (NCT03633721)
- 2025-09-11Results posted on the registry: Defined Research, Defined CBD + Placebo (NCT05233761)
- 2025-08-29Phase 3 first posted: Johns Hopkins University, Cannabidiol (CBD) + Placebo (NCT07148843)
- 2025-08-29Phase 3 first posted: Montefiore Medical Center, Dronabinol Capsules + Epidiolex 100 mg/mL Oral Solution (NCT07148206)
- 2025-08-19Results posted on the registry: Yale University, [18F]FPEB with PET (NCT05664763)
- 2025-08-19Also stopped (terminated): Yale University, [18F]FPEB with PET (NCT05664763)
- 2025-08-14Phase 3 first posted: Wayne State University, Low-Dose Cannabidiol + Placebo Matched to Moderate-Dose Cannabidiol (NCT07123467)
- 2025-08-14Results posted on the registry: Medical University of South Carolina, Cannabidiol (NCT05317546)
- 2025-08-07Results posted on the registry: University of Florida, oral cannabinoid + oral codeine/acetaminophen (NCT05477875)
- 2025-08-06Results posted on the registry: University of Florida, Active CBD + Vehicle Control (Placebo) (NCT04586712)
- 2025-08-01Results posted on the registry: University of California, Los Angeles, Cannabidiol (CBD) 600 mg + Placebo (NCT03787628)
- 2025-07-31Results posted on the registry: Food and Drug Administration (FDA), Cannabidiol + Placebo (NCT06192589)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision